Figure 3
From: Extraskeletal myxoid chondrosarcoma: tumor response to sunitinib
Computed Tomography scan (CT) tumor assessment. In panels A, B, C (white arrows) CT, venous phase, after contrast medium, shows a peritoneal metastasis at baseline, after 1 and 4 months of sunitinib with evidence of 30% decrease in tumor size and contrast uptake. Panel D shows an interval tumor progression at 6 months from baseline, i.e. after 2 months from sunitinib interruption, while panel E shows a new response at 7 months, 4 weeks after restoring sunitinib.